Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Brentuximab Vedotin in Combination With Bendamustine and Rituximab, in Patients With CD30 Positive, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (NHL)

NCT02623920 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.

NCT NCT02623920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02623920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Brentuximab Vedotin in Combination With Bendamustine and Rituximab, in Patients With CD30 Positive, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (NHL)
Lead sponsor
University of Arizona
Phase
Phase 2
Overall status
Withdrawn
Start date
December 16, 2015
Completion date
May 17, 2017
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, follicular lymphoma, grey zone lymphoma, high grade b cell lymphoma, marginal zone lymphoma, mediastinal large b-cell lymphoma, small lymphocytic lymphoma